Amylyx Pharmaceuticals (AMLX)

• Market cap: $274M
• 1 day: -1.72%
• 5 days: -6.10%
• 1 month: -29.33%
• 3 months: 32.89%
• 6 months: 118.58%
• Year to date: -73.28%
• 1 year: -71.91%
• 5 years: -77.86%
• 10 years: -77.86%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder.

Employees: 384

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

66% more capital invested

Capital invested by funds: $84.7M [Q2] → $141M (+$56M) [Q3]

9% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 35

1.76% less ownership

Funds ownership: 65.52% [Q2] → 63.76% (-1.76%) [Q3]

8% less funds holding

Funds holding: 119 [Q2] → 109 (-10) [Q3]

31% less first-time investments, than exits

New positions opened: 22 | Existing positions closed: 32

74% less call options, than puts

Call options by funds: $796K | Put options by funds: $3.04M

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $11 175% upside
• Avg. target: $11.50 188% upside
• High target: $12 200% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 102 / 328 met price target	200% upside $12	Buy Reiterated	5 Dec 2024
Baird Joel Beatty 48% 1-year accuracy 21 / 44 met price target	175% upside $11	Outperform Upgraded	18 Nov 2024